Fig. 7

Influence of FMT treatment on inflammation-related signaling pathways in the brain of APP/PS1 mice. (A) Representative images of hippocampal TLR4, NF-κB, COX-2, MyD88, IL-6, IL-1β and TNF-α in Western blot experiments. (B-H) Quantification of TLR4 (F = 9.016; P = 0.0156; df = 8) (n = 3 for each group), NF-κB p65(F = 7.862; P = 0.0211; df = 8) (n = 3 for each group), COX-2 (F = 13.44; P = 0.0061; df = 8) (n = 3 for each group), MyD88 (F = 6.879; P = 0.0280; df = 8) (n = 3 for each group), IL-6(F = 9.593; P = 0.0135; df = 8) (n = 3 for each group), IL-1β (F = 16.40; P = 0.0037; df = 8) (n = 3 for each group) and TNF-α (F = 8.155; P = 0.0195; df = 8) (n = 3 for each group) proteins in hippocampus according to Western blot results. (I-K) Expression of mRNA for IL-6 (F = 10.78; P = 0.0103; df = 8) (n = 3 for each group), IL-1β (F = 10.98; P = 0.0099; df = 8) (n = 3 for each group) and TNF-α (F = 12.53; P = 0.0072; df = 8) (n = 3 for each group) in the hippocampus. Data were analyzed using one-way ANOVA, followed by Tukey’s multiple comparisons test (B-I, K) and Kruskal-Wallis test, followed by Dunn’s multiple comparisons test (J). Data were expressed as mean ± SD. *P < 0.05; **P < 0.01